Company Tempest Therapeutics, Inc.

Equities

TPST

US87978U1088

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-08 pm EDT			5-day change	1st Jan Change
2.1 ^USD	+3.96%		-1.87%	-52.27%

Jul. 01	Tempest Therapeutics, Inc.(NasdaqCM:TPST) added to Russell Microcap Growth Index	CI
Jul. 01	Tempest Therapeutics, Inc.(NasdaqCM:TPST) added to Russell 3000E Index	CI

Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR). The ongoing global randomized Phase Ib/II trial of TPST-1120 combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). The Companyâs second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, is in an ongoing Phase I combination trial in patients with endometrial cancer.

Number of employees: 17

Managers	Title	Age	Since
Stephen Brady CEO	Chief Executive Officer	54	19-08-31
Nicholas Maestas DFI	Director of Finance/CFO	44	21-07-11
Darrin Bomba CTO	Chief Tech/Sci/R&D Officer	-	21-11-30
Sam Whiting CTO	Chief Tech/Sci/R&D Officer	58	20-10-31
Justin Trojanowski AUD	Comptroller/Controller/Auditor	36	22-05-31
Sharon Sakai LAW	General Counsel	-	-

Members of the board	Title	Age	Since
Christine Pellizzari BRD	Director/Board Member	56	21-06-30
Geoffrey Nichol BRD	Director/Board Member	69	19-11-30
Mike Raab Raab CHM	Chairman	59	20-12-31
Ronit Simantov BRD	Director/Board Member	59	21-08-05
Stephen Brady CEO	Chief Executive Officer	54	19-08-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	22,217,265	22,195,864 ( 99.90 %)	0	99.90 %

Name	Equities	%	Valuation
Versant Venture Management LLC 19.33 %	4,295,055	19.33 %	9 M $
BlackRock Institutional Trust Co. NA 2.287 %	508,195	2.287 %	1 M $
Impresa Management LLC 1.944 %	431,932	1.944 %	945 931 $
Vanguard Global Advisers LLC 0.7930 %	176,193	0.7930 %	385 863 $
Geode Capital Management LLC 0.5945 %	132,083	0.5945 %	289 262 $
FIL Ltd. (Subfiler) 0.5832 %	129,579	0.5832 %	283 778 $
Ikarian Capital LLC 0.4753 %	105,600	0.4753 %	231 264 $
Bank of America, NA (Charlotte, North Carolina) 0.1937 %	43,029	0.1937 %	94 234 $
STATE STREET CORPORATION 0.1868 %	41,492	0.1868 %	90 867 $
Simplex Trading LLC 0.1702 %	37,820	0.1702 %	82 826 $

Tempest Therapeutics, Inc.

2000 Sierra Point Parkway Suite 400

94005, Brisbane

http://www.tempesttx.com

address Tempest Therapeutics, Inc.(TPST)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.1 USD

Average target price

18.6 USD

Spread / Average Target

+785.71%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
TEMPEST THERAPEUTICS, INC.	-52.27%	46.66M
MODERNA, INC.	+17.09%	44.63B
LONZA GROUP AG	+46.11%	40.46B
IQVIA HOLDINGS INC.	-9.70%	38.07B
ALNYLAM PHARMACEUTICALS, INC.	+33.28%	32.27B
CELLTRION, INC.	-8.98%	27.3B
ICON PUBLIC LIMITED COMPANY	+13.37%	26.53B
UNITED THERAPEUTICS CORPORATION	+44.11%	14.06B
MEDPACE HOLDINGS, INC.	+32.33%	12.54B
BIO-TECHNE CORPORATION	-7.26%	11.28B

Other Biotechnology & Medical Research